|
| Alcon drops AMD candidate
| | July 21, 2008 | Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD). |
| | Chemotherapy can save eyes
| | July 21, 2008 | | A direct ophthalmic artery infusion of melphalan for retinoblastoma can enable eyes designated as enucleated to be salvaged, according to a study published in the July 2008 issue of Ophthalmology. |
| | Geuder discusses new products
| | July 21, 2008 | | Geuder Group discussed several new products, including Brilliant Peel vitreoretinal fluid dye and Siluron 2000, during a posterior segment symposium at this year's Euretina meeting. |
| | DR not main cause of blindness in diabetics
| | July 14, 2008 | | Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology. |
| | Nutraceutical helps patient see clearly
| | July 14, 2008 | | Longevinex (Resveratrol), a nutraceutical matrix, can remove lipofuscin deposits from the retina to improve visual acuity and night vision, according to research presented at this year's meeting of the American Academy of Optometry in Seattle, US. |
|
|
|
| Fundus autofluorescence imaging betters armamentarium
| | June 25, 2008 | | Fundus autofluorescence imaging, one of the modes available in a new instrument (Spectralis HRA+OCT, Heidelberg Engineering), enhances its utility as a diagnostic device and a tool for monitoring therapy of patients with retinal and macular diseases. |
| | Combination therapies for AMD pose an intriguing avenue for research
| | June 18, 2008 | | The Verteporfin Intravitreal Triamcinolone Acetonide Study (VERITAS) of intravitreal triamcinolone acetonide (Kenalog, Bristol-Myers Squibb) or pegaptanib (Macugen, Pfizer) in combination with photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Pharmaceuticals) was underpowered to reach definitive conclusions about the therapies. |
| | | Fewer retreatments with combination AMD therapy
| | May 1, 2008 | | Providing patients with renewed hope and the chance of halting and maybe even reversing vision loss, the launch of this anti-VEGF therapy has signalled a permanent change in the way this debilitating disorder is treated worldwide. |
| |
|
| 
